Sourcing Pirfenidone (Pirfenex) for Pulmonary Fibrosis: Refrigerated Handling and Volume Planning

Overview

Antifibrotic therapy is bought differently from oncology therapy: treatment runs for years rather than cycles, and the purchasing question shifts from case volume to continuity of resupply. Pirfenex, the Pirfenidone presentation listed here with refrigerated storage specified, sits in that long-horizon category, and its titration schedule makes early-month and steady-state consumption look nothing alike.

How It Works

Pirfenidone acts on several profibrotic pathways at once rather than one receptor. It dampens transforming growth factor beta signalling, reduces fibroblast proliferation and collagen deposition, and attenuates tumour necrosis factor alpha and interleukin production. Because no single molecular target defines its activity, no companion test gates eligibility, which removes a diagnostic bottleneck from the ordering process. What remains is a supply commitment: interrupted resupply means lost lung function that does not return.

Indications

The primary registered use is idiopathic pulmonary fibrosis in adults, aimed at slowing decline in forced vital capacity. Regional labels extend to selected progressive fibrosing interstitial lung diseases. Prescribing typically follows multidisciplinary confirmation using high-resolution CT, sometimes supported by biopsy, and continues indefinitely while tolerated.

Dosage & Administration

Treatment escalates over two weeks. Days one to seven use 267mg three times daily, days eight to fourteen move to 534mg three times daily, and from day fifteen onward the maintenance dose is 801mg three times daily, totalling 2403mg per day. Doses are taken with food to limit nausea, and patients are advised on strict photoprotection because photosensitivity is common. Liver enzymes are checked before starting and periodically after.

Storage & Sourcing

Respect the refrigerated specification on this presentation: hold at 2-8°C, avoid freezing, and keep packs in outer cartons to block light. Practical procurement points follow from the titration curve. A patient at maintenance consumes nine tablets daily, so annual per-patient volume is high and stable, which supports negotiated MOQ tiers rather than spot buying. Request at least eighteen months of remaining shelf life, insist on batch-level certificates of analysis, and verify that the cold-chain leg into the destination market is contracted rather than assumed.

FAQ

Q: How much does the two-week titration change first-month order size? Considerably. Week one uses three tablets daily against nine at maintenance, so a first month runs roughly two-thirds of steady-state volume.

Q: What remaining shelf life should a buyer insist on for refrigerated antifibrotic stock? Eighteen months or more. Chronic therapy turns over predictably, but cold-chain stock that ages in a depot becomes unsellable quickly.

Q: Is dry-ice shipping appropriate for this product? No. Dry ice risks freezing, which is excluded. Use validated 2-8°C shippers with gel packs and a calibrated logger per carton.

Q: How should photosensitivity counselling be reflected in a wholesale package? Supply the patient leaflet in the destination language alongside the cartons; pharmacies increasingly require local-language photoprotection guidance before dispensing.